HC Wainwright & Co. Reiterates Buy Rating on BBIO | BBIO Stock N - GuruFocus
Yesterday • Google News
BridgeBio Pharma Inc (BBIO)
US$ 00%
Price Chart
Key Statistics
Market Cap
$ 9.84B
P/E Ratio
0.00
Revenue (TTM)
$ 235.81M
Volume
0
52W High
$ 54.60
52W Low
$ 21.72
Dividend Yield
0.00%
Beta
1.25
Technicals
50-Day MA
48.5367
200-Day MA
37.6142
52 Week High
54.6
52 Week Low
21.72
About BBIO
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
Employees
725
Headquarters
Palo Alto, CA
CEO
Dr. Neil Kumar Ph.D.
Latest News
New Analyst Forecast: $BBIO Given $82.0 Price Target - Quiver Quantitative
4 days ago • Google News
Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy - MSN
3 days ago • Google News